Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro Biopharma's revenue per share for the
three
months ended in Jun. 2026 was $0.59.
Sutro Biopharma's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $4.18.
Warning Sign:
Sutro Biopharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Sutro Biopharma was -66.20% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -3.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -3.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Sutro Biopharma's Revenue per Share or its related term are showing as below:
STRO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -43.8 Med: -15.8 Max: 24.9
Current: -3.3
During the past 10 years, Sutro Biopharma's highest 3-Year average Revenue Per Share Growth Rate was 24.90% per year. The lowest was -43.80% per year. And the median was -15.80% per year.
STRO's 3-Year Revenue Growth Rate is ranked worse than 57.87% of 769
companies
in the Biotechnology industry
Industry Median: 3
vs STRO: -3.30
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Sutro Biopharma Revenue per Share Related Terms
Sutro Biopharma Revenue per Share Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STRO vs AVIR, IPSC, CCCC: Revenue per Share Comparison
For the Biotechnology subindustry, Sutro Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Sutro Biopharma's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (STRO) has a Revenue per Share of $4.18 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #445 out of 769 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Sutro Biopharma's Revenue per Share too high?
Sutro Biopharma's current Revenue per Share is $4.18. The Biotechnology industry median Revenue per Share is 3.00. Sutro Biopharma's value of $4.18 is 39.3% above this industry median. Based on the distribution chart, Sutro Biopharma ranks #445 out of 769 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Revenue per Share compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #445 out of 769 companies for Revenue per Share. This places Sutro Biopharma in the lower half of its industry. The industry median Revenue per Share is 3.00. Sutro Biopharma's value of $4.18 is 39.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.00, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current Revenue per Share of $4.18 is 39.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Sutro Biopharma and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Revenue per Share is $4.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current Revenue per Share is $4.18 and 39.3% above the Biotechnology industry median of 3.00. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Revenue per Share is $4.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
Revenue per Share: $4.18
GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
Industry Position: 39.3% above the Biotechnology median (#445 of 769)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
